Background. The spread of carbapenem resistance in Enterobacteriacae (CRE) and PA is an urgent public health concern. Candida auris (CA) is also an emerging threat, with the epicenter of US cases on the East Coast. Transcontinental spread of multi-drug-resistant (MDR) organisms has the potential to change local susceptibility patterns via dissemination of resistance determinants or high-risk clones. Here, we report and characterize MDR-isolates of EC, KP, PA and CA, all isolated from a single patient admitted to an ICU in Houston, Texas after complications from plastic surgery in India.
Methods. CRE were isolated from the urine, PA from respiratory cultures and CA from wound cultures. Antimicrobial susceptibility testing was performed on Vitek 2 or by Etest. Synergy testing was done by Aztreonam (ATM) E-test on Mueller-Hinton agar supplemented with 2.2 µg/mL avibactam. Bacterial isolates underwent whole genome sequencing on an Illumina MiSeq, and resistance determinants (Abricate using CARD), plasmid replicon types (PlasmidFinder 1.3) and sequence type (Tseemann MLSTtool) were identified. Genes were verified by PCR.
Results. The CRE were resistant to all β-lactams, including ceftazidime/avibactam (CZA) and ceftolozane/tazobactam. Synergy testing with CZA+ATM reduced the ATM MICs of the EC from >256 to 0.5 µg/mL and the KP from >256 to .094 µg/mL, while the PA ATM MIC was 4 µg/mL irrespective of the presence of avibactam. WGS indicated that the EC and KP shared the bla NDM-5 , bla , and bla CTX-M-15 β-lactamase genes, as well as IncFII and IncX3 plasmid replicon types. In addition, the EC harbored bla , bla OXA-181 , qnrS1 and two additional IncB and IncY plasmid replicon types. The PA isolate harbored bla NDM-1 , qnrVC1, several aminoglycoside resistance genes and a type 1 integrase. The CA isolate had a fluconazole MIC of >256 µg/mL and a micafungin MIC of 0.125 µg/mL.
Conclusion. Here we report the identification of 4 MDR organisms, including the first reported isolate of CA in Houston, in one patient. The pattern of resistance determinants suggests horizontal transmission of bla Kp. Here, we tested various agents in combination with CZA for synergistic and bactericidal activity.
Methods. We tested isolates for responses to CZA alone (1 and 4× MIC; avibactam fixed at 4 µg/mL), and in combination with colistin (COL; 2 µg/mL), fosfomycin (FOS; 100 µg/mL + 25 µg/mL G6P), gentamicin (GEN; 2 µg/mL), MER (8 µg/mL), and tigecycline (TGC; 2 µg/mL) by time-kill using a starting inoculum of 1 × 10 8 cFu/ mL. Log-kills were calculated as log cFu/mL decrease from time 0; 24 hours was the primary endpoint.
Results. Thirty KPC-Kp isolates were studied (22 KPC-2 and 8 KPC-3); all isolates were CZA-susceptible (MIC range: 0.125-4 µg/mL). Fifty-three percent harbored ompK36 mutations (eight each with IS5 and 134-135 DG insertions). Mean log-kills by CZA at 1× and 4× MIC were 2.00 and 2.35, respectively; CZA was bactericidal (≥3-log kill) at 24 hours against 33% and 50%, respectively. CZA mean log-kills at 4× MIC were greater for KPC-3 (3.81) than KPC-2 (1.82) isolates (P = 0.03), but did not vary by porin genotype (P = 0.44). GEN was the most active single agent and was bactericidal against 57%; the mean log-kill was 3.06. In combination with CZA, rates of synergy (>2-log kill in combo) with COL, FOS, GEN, MER, and TGC were 83%, 60%, 40%, 87%, and 7%, respectively. The corresponding rates of bactericidal activity were 87%, 77%, 80%, 100%, and 30%, respectively. Antagonism (>1-log kill by most active single agent) was identified in 7%, 23%, 20%, 0%, and 27% with CZA + COL, FOS, GEN, MER, and TGC, respectively. Mean log-kills by CZA + MER were greater among isolates with wild-type (6.58) vs. mutant (5.48) ompK36 (P = 0.0006), and isolates harboring KPC-3 (7.02) vs. KPC-2 (5.63; P = 0.0004). CZA + COL responses were attenuated among isolates with COL MICs ≥2 (log-kills 2.88 vs. 7.94; P = 0.0009), but not affected by ompK36 genotype (P = 0.53). Among isolates with COL MICs <2; log-kills were greater for CZA + COL (7.94) than CZA + MER (6.44; P < 0.0001).
Conclusion. A two-drug combination of CZA + MEM results in high rates of synergy and bactericidal activity against genetically diverse KPC-Kp. Mean log-kills were less among isolates with mutations in ompK36. CZA + COL was highly active against isolates ompK36 mutations, but contingent on COL susceptibility. Methods. We assembled a CRISPR-Cas9 system for gene knockouts (KO) in CRE K. pneumoniae (CRKP) using zeocin as a selectable marker. We chose a polymyxin susceptible (PS) and a PR isolate with a missense mutation in crrB (L87V) (NR5337 and NR5083, respectively) for KO. Isolates were transformed with a crrB KO plasmid, grown with zeocin selection, induced with arabinose, and plated on low-salt LB-zeocin/arabinose. KOs were confirmed via PCR and Sanger sequencing. Polymyxin susceptibility was performed with broth-microdilution. Gene expression was determined by qRT-PCR of cDNA extracts.
Results. Colistin MIC following crrB KO of NR5337 (PS) remained unchanged. In contrast, crrB KO of NR5083 (PR), decreased polymyxin MIC (MIC >128 to 1.0 μg/ mL). qRT-PCR of NR5083 did not show increased expression of pmrA/C, nor pmrK. NR5083 ^crrB showed a small decrease in phoQ expression, compared with NR5083, but similar expression of phoP, pmrA/C and pmrK (Table 1) .
Conclusion. Polymyxin MIC decreased >128 fold after crrB KO in a PR isolate, but colistin MIC remained unchanged after KO in a PS isolate. CrrB mutations in PR isolates may confer a gain of function with CrrB acting as a positive regulator on its downstream targets. Contrary to previous literature, no upregulation of pmrA/C and pmrHFIJKLM was detected. Differences in crrB mutations or clonal background may explain this finding. CRISPR-Cas9 may serve as a reliable system for genetic manipulation of CRKP. Further data on the impact of individual crrB missense mutations are needed.
